Search PubMed⌕ Search

Biomedical subjects

Y Mine

Publications and source records attributed to Y Mine.

At least 91 records · Page 5Linked to original sources
PubMed1986

[Four cases of male breast cancer including one synchronously combined with gastric cancer].

Four men with primary breast cancer were seen between 1972 and 1985 at the Sasebo Municipal Hospital. They were admitted complaining of breast mass and/or bloody nipple discharge. There was no delay between the onset of symptoms and seeking medical advice. They had relatively early stages of disease (three patients had stage I and one had stage II). All patients were treated by modified radical or radical mastectomy. Histopathological study revealed ductal carcinomas and no lymph node metastasis in all patients. Multiple bone metastasis and death occurred in one case. One patient (61 years old) had two separate synchronous primary cancers of the breast and stomach, which is very uncommon.

Adenocarcinoma, Papillary↗
PubMed1986

Protective effect of Nocardia rubra cell wall skeleton on experimental infection in normal and immunosuppressed mice.

The protective effect of Nocardia rubra cell wall skeleton (N-CWS) on experimental infections was investigated in normal and immunosuppressed mice. Pretreatment with N-CWS provided protection against acute systemic infections due to Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Serratia marcescens and Listeria monocytogenes in normal mice. N-CWS administered before or after challenge also showed protective activity against Herpes simplex virus infection in normal mice. N-CWS was the most effective against extracellular parasitic Pseudomonas aeruginosa infection when administered 1 day before challenge, but displayed the most potent protective activity against infection with Listeria monocytogenes, a facultative intracellular parasite, when administered 7 to 14 days before challenge. In mice with subcutaneous Pseudomonas aeruginosa infection, N-CWS suppressed abscess formation and decreased the viable cell count in the resultant abscess foci when administered either intraperitoneally or subcutaneously to the infected site. In addition, treatment with N-CWS markedly restored host defense ability against pseudomonal infection in mice immunosuppressed with cyclophosphamide, hydrocortisone and X-ray irradiation.

Animals↗
PubMed1986

In vivo activation of functional properties in mouse peritoneal macrophages by Nocardia rubra cell wall skeleton.

Exudative cells in the peritoneal cavity of mice, particularly polymorphonuclear leukocytes significantly increased 1 day after intraperitoneal injection of Nocardia rubra cell wall skeleton (N-CWS). Macrophages and lymphocytes significantly increased 4 to 7 days after injection. N-CWS also enhanced peritoneal macrophage functions such as phagocytosis of latex particles, production of superoxide anion, production and secretion of lysosomal enzymes such as beta-glucuronidase, lysozyme and acid phosphatase, phagocytosis and intracellular killing of bacteria, and in vitro chemotaxis. The phagocytic function of the reticuloendothelial system was also enhanced. These results indicate that macrophages were activated in vivo by N-CWS.

Animals↗
PubMed1986

Effect of Nocardia rubra cell wall skeleton on humoral and cellular factors related to immune response in mice and guinea pigs.

The in vitro and in vivo effects of Nocardia rubra cell wall skeleton (N-CWS) on induction of serum ceruloplasmin, hemopexin, haptoglobin, complement and interferon in mice and guinea pigs are described. After intraperitoneal administration of N-CWS to mice, serum hemopexin increased markedly and also induced an increase of haptoglobin, but not of ceruloplasmin. The drug activated complement in vitro but did not affect serum complement level in guinea pigs. Intravenous N-CWS induced serum interferon in mice, although there were strain differences. Addition of N-CWS to mouse spleen cell culture also induced interferon. Intraperitoneal N-CWS increased peritoneal cells in mice: in particular polymorphonuclear leukocytes increased soon after dosing, followed by macrophages and lymphocytes. However, the drug did not affect peripheral leukocyte counts or alter peripheral cell population.

Animals↗
PubMed1985

Regulation of expression of the cloned ada gene in Escherichia coli.

The ada gene of Escherichia coli K12, the regulatory gene for the adaptive response of bacteria to alkylating agents, was cloned in multicopy plasmids. O6-Methylguanine-DNA methyltransferase and 3-methyladenine-DNA glycosylase II, which are known to be inducible as part of the adaptive response, were produced in ada- cells bearing ada+ plasmids, even without treatment with alkylating agents. When such cells had been treated with methyl methanesulfonate, even higher levels of the enzyme activities were produced. Maxicell experiments revealed that the ada gene codes for a polypeptide with a molecular weight of 38 000. We constructed a hybrid plasmid carrying an ada'-lacZ' fused gene, with the proper control region for ada expression. beta-Galactosidase synthesis from the fused gene was strongly induced only when cells were treated with low doses of methylating agents, but was weakly induced with relatively high doses of ethylating agents. The induction was autogenously regulated by the ada gene product, in a positive manner.

Alkylating Agents↗
PubMed1985

Mechanism of renal excretion of FK027 in dogs and rabbits.

The mechanism of renal excretion of FK027, a new oral cephalosporin, was investigated in dogs and rabbits. In dogs, FK027 was mainly cleared by glomerular filtration, and approximately 50% of the filtered drug was reabsorbed through the proximal tubules. This tubular reabsorption and a high binding ratio to serum protein lead to the exceptionally long serum half-life of the drug. The facts that the clearance ratio of FK027 declined slightly from 58.0 to 49.2% by the addition of probenecid, and that the effect of probenecid was less marked in the stop-flow study, along with no significant change in serum half-life, may account for the scarcely detectable secretion from the renal tubules. In rabbits, the addition of probenecid caused a decrease of the clearance ratio of FK027, disappearance of FK027 peak in the stop-flow study, and extended the serum half-life. These facts are evidence that FK027 is excreted by both tubular secretion and glomerular filtration in rabbits.

Absorption↗
PubMed1985

Immunoactive peptides, FK 156 and FK 565. IV. Activation of mouse macrophages.

We investigated the effects of the immunoactive peptides, FK 156 and FK 565, on functions of mouse macrophages. FK 156 and FK 565 given parenterally or orally to mice enhanced spreading of peritoneal macrophages, phagocytosis of latex particles and intracellular killing of bacteria by peritoneal macrophages. FK 156 and FK 565 also enhanced the production of superoxide anion and lysosomal enzyme activities of macrophages. The peptides also activated mouse spleen macrophages, and the kinetics of this activation differed from that of the peritoneal macrophages. In addition, both drugs directly enhanced the production of superoxide anion by mouse peritoneal macrophages treated in vitro and enhanced the functions of peritoneal macrophages of athymic nude mice. Both these phenomena suggest that direct activation might be one of the mechanisms of macrophage activation by the peptides.

Adjuvants, Immunologic↗
PubMed1985

Pharmacokinetics of FK027 in rats and dogs.

The pharmacokinetics of FK027, a new oral cephalosporin, were investigated in rats and dogs and compared with those of cefaclor, cephalexin and amoxicillin. Upon oral administration to either rats or dogs, FK027 produced higher and more sustained serum levels than the reference drugs, hence a longer half-life. After both oral and intravenous administration, the half-life of FK027 in dogs was approximately three fold that in rats. Although the concentrations of FK027 in rat kidney, liver and spleen were lower than those of cephalexin and amoxicillin, they were sustained similarly to the serum levels. The 24-hour urinary and biliary recovery rates of FK027 in rats after oral dosing with 100 mg/kg were 34.1 and 21.9%, respectively. The urinary excretion of FK027 was significantly lower than that of the reference drugs, however, the biliary excretion was higher. In dogs, 23.4 and 0.2% of the given dose of 40 mg/kg of FK027 was excreted in the 24-hour urine and bile, respectively. Bioavailability of FK027 after oral dosing was 38% in rats and 47% in dogs, as calculated from intravenous data. Binding of FK027 to serum protein in all species was the highest of the test drugs: 63% for human, 93% for dog, 61% for rat serum.

Animals↗
PubMed1984

In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.

FK 027 was more active than cefaclor, cephalexin, and amoxicillin against stock strains of a wide variety of gram-negative bacteria, including such opportunistic pathogens as Citrobacter and Enterobacter species and Serratia marcescens. FK 027 was significantly more active than the three reference drugs against clinical isolates of Escherichia coli, Klebsiella pneumoniae, indole-positive and -negative Proteus species, Providencia species, Haemophilus influenzae, and Neisseria gonorrhoeae. It was less active than cefaclor, cephalexin, and amoxicillin against staphylococci, but it was similar to cefaclor in its activity against streptococci. With few exceptions, FK 027 was active against strains of E. coli, K. pneumoniae, and Proteus mirabilis that were resistant to the reference agents. The bactericidal activity of FK 027 against various gram-negative bacteria, including Proteus species, Citrobacter freundii, Enterobacter aerogenes, and S. marcescens, was greater than that of cefaclor, cephalexin, and amoxicillin. The therapeutic activities of FK 027 in mice infected with gram-negative bacilli were far superior to the activities of cefaclor, cephalexin, and amoxicillin, but they were inferior to the activities of these reference drugs against infection with Staphylococcus aureus.

Amoxicillin↗
PubMed1984

[Epidemiology of lung cancer in Nagasaki--especially in relation to radiation exposure].

We investigated the present incidence of lung cancer and its distribution by histologic type in Nagasaki City using Nagasaki Tumor Registry data from the years 1973-1977. The risk of radiogenic lung cancer did not increase significantly in either sex. The difference in relative distribution by histologic type between the exposure and non-exposure groups was not significant. Further analyses should be carried out on the risk present for individuals who were young at the time the bomb was dropped and the effect of exposure distance on the incidence and histologic types of lung cancer in A-bomb survivors.

Adenocarcinoma↗
PubMed1983

Immunoactive peptides, FK-156 and FK-565. I. Enhancement of host resistance to microbial infection in mice.

The protective effect of an immunoactive peptide, D-lactoyl-L-alanyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(L)-glycine (FK-156) and a related compound, heptanoyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alanine (FK-565) was determined in mice with various kinds of microbial infections. FK-156 and FK-565 were given to mice either subcutaneously or orally before challenge. The drugs enhanced significantly the defense of mice against acute systemic infections induced by various extracellular and facultative intracellular organisms, and subcutaneous abscess by Staphylococcus aureus. The protective effect of these drugs against Escherichia coli infection differed considerably depending on the route of administration; FK-156 was only effective by the parenteral route; however, FK-565 was effective by both parenteral and oral routes. After subcutaneous dosing with FK-156, the enhancement of host defense of mice against E. coli infection was more rapid than against Listeria infection. The enhancing effects of FK-156 and FK-565 on host defense of mice against pseudomonal infection was more potent than other immunoactive drugs.

Adjuvants, Immunologic↗
PubMed1983

Immunoactive peptides, FK-156 and FK-565. II. Restoration of host resistance to microbial infection in immunosuppressed mice.

The immunoactive peptides, FK-156 and its analogue, FK-565 were evaluated in various models of mice immunosuppressed with cyclophosphamide, hydrocortisone, mitomycin C, carrageenan and tumor cells. Treatment with FK-156 (subcutaneous) and FK-565 (oral) markedly restored host defense ability against microbial infection. The therapeutic effect of ticarcillin or gentamicin alone against pseudomonal infection in cyclophosphamide- and hydrocortisone-treated mice and tumor-bearing mice was much lower than in normal mice. The therapeutic effect of these antibiotics against pseudomonal infection in immunosuppressed mice was enhanced markedly by combined use with FK-156. The killing ability of macrophages and polymorphonuclear leukocytes of the immunosuppressed mice was also markedly enhanced by dosing with FK-156.

Adjuvants, Immunologic↗